GSK (MEX:GSKN) Piotroski F-Score: 8 (As of Jun. 24, 2026) — 33% Above Median


MEX:GSKN GSK PLC MEX:GSKN
73 GF Score
Price MXN901.11
GF Value MXN818.82
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is GSK Piotroski F-Score?

GSK MEX:GSKN 73 Piotroski F-Score is 8 as of Jun. 24, 2026, which is 33% above its 10-year median of 6.00. GuruFocus rates MEX:GSKN with a GF Score™ of 73/100 and a GF Value™ of MXN818.82 (Fairly Valued). The stock has 1 warning sign investors should review. Among 981 Drug Manufacturers companies, GSK ranks better than 98.37% on this metric.

Good Sign:

Piotroski F-Score is 8, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

GSK has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for GSK's Piotroski F-Score or its related term are showing as below:

MEX:GSKN' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 9
Current: 8

During the past 13 years, the highest Piotroski F-Score of GSK was 9. The lowest was 4. And the median was 6.

GSK  (MEX:GSKN) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


GSK Piotroski F-Score Related Terms


GSK Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for GSK's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GSK Piotroski F-Score Chart

GSK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 7.00 5.00 5.00 9.00

GSK Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 6.00 8.00 9.00 8.00

MEX:GSKN vs LLY, JNJ, ABBV: Piotroski F-Score Comparison

For the Drug Manufacturers - General subindustry, GSK's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GSK Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GSK's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where GSK's Piotroski F-Score falls into.


MEX:GSKN
73GF Score
GSK PLC MEX:GSKN
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 36866.398 + 49901.182 + 15330.154 + 41763.733 = MXN143,861 Mil.
Cash Flow from Operations was 53549.529 + 55082.179 + 54908.949 + 27433.748 = MXN190,974 Mil.
Revenue was 204029.839 + 211875.51 + 207728.41 + 183428.624 = MXN807,062 Mil.
Gross Profit was 148717.467 + 155900.911 + 143684.04 + 138346.874 = MXN586,649 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(1604541.384 + 1513949.435 + 1520560.654 + 1473189.254 + 1511597.088) / 5 = MXN1524767.563 Mil.
Total Assets at the begining of this year (Mar25) was MXN1,604,541 Mil.
Long-Term Debt & Capital Lease Obligation was MXN336,899 Mil.
Total Current Assets was MXN427,038 Mil.
Total Current Liabilities was MXN539,274 Mil.
Net Income was 27340.306 + -1510.631 + 10915.626 + 42925.216 = MXN79,671 Mil.

Revenue was 183760.422 + 208675.507 + 214014.813 + 198661.281 = MXN805,112 Mil.
Gross Profit was 134300.806 + 146244.755 + 146543.591 + 147462.917 = MXN574,552 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(1233879.894 + 1353403.436 + 1511907.705 + 1567816.042 + 1604541.384) / 5 = MXN1454309.6922 Mil.
Total Assets at the begining of last year (Mar24) was MXN1,233,880 Mil.
Long-Term Debt & Capital Lease Obligation was MXN435,437 Mil.
Total Current Assets was MXN478,019 Mil.
Total Current Liabilities was MXN550,600 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

GSK's current Net Income (TTM) was 143,861. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

GSK's current Cash Flow from Operations (TTM) was 190,974. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=143861.467/1604541.384
=0.08965893

ROA (Last Year)=Net Income/Total Assets (Mar24)
=79670.517/1233879.894
=0.0645691

GSK's return on assets of this year was 0.08965893. GSK's return on assets of last year was 0.0645691. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

GSK's current Net Income (TTM) was 143,861. GSK's current Cash Flow from Operations (TTM) was 190,974. ==> 190,974 > 143,861 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=336898.923/1524767.563
=0.220951

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=435437.192/1454309.6922
=0.2994116

GSK's gearing of this year was 0.220951. GSK's gearing of last year was 0.2994116. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=427038.38/539273.904
=0.79187659

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=478018.795/550600.471
=0.86817724

GSK's current ratio of this year was 0.79187659. GSK's current ratio of last year was 0.86817724. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

GSK's number of shares in issue this year was 2037. GSK's number of shares in issue last year was 2068.5. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=586649.292/807062.383
=0.7268946

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=574552.069/805112.023
=0.71362997

GSK's gross margin of this year was 0.7268946. GSK's gross margin of last year was 0.71362997. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=807062.383/1604541.384
=0.50298633

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=805112.023/1233879.894
=0.65250437

GSK's asset turnover of this year was 0.50298633. GSK's asset turnover of last year was 0.65250437. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+0+1+1+0
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

GSK has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 8 mean?
GSK (MEX:GSKN) has a Piotroski F-Score of 8 as of Jun. 24, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on GSK and its competitors. This is 33% above median its historical median of 6.00. Over the past decade, GSK's Piotroski F-Score has ranged from 4.00 to 9.00. According to the industry distribution chart, GSK ranks #16 out of 981 companies in the Drug Manufacturers industry, placing it in the top 1.6%.
Is GSK's Piotroski F-Score too high?
GSK's current Piotroski F-Score of 8 is 33% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 9.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. GSK's value of 8 is 60% above this industry median. Based on the distribution chart, GSK ranks #16 out of 981 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, GSK has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GSK's Piotroski F-Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GSK ranks #16 out of 981 companies for Piotroski F-Score. This places GSK in the top 2% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. GSK's value of 8 is 60% above this benchmark. Historically, GSK's own Piotroski F-Score has ranged from 4.00 to 9.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, GSK has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GSK's current Piotroski F-Score of 8 is 60% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on GSK and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GSK's current Piotroski F-Score is 8, which is 33% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (MEX:GSKN) is currently considered Fairly Valued. The stock's GF Value™ is MXN818.82, compared to a current price of MXN901.11 — trading 10% above its estimated fair value. The current Piotroski F-Score is 8, which is 33% above median its 10-year median of 6.00 and 60% above the Drug Manufacturers industry median of 5.00. GSK's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For GSK (MEX:GSKN), the current Piotroski F-Score is 8 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GSK (MEX:GSKN) Overvalued in 2026?

Based on GuruFocus' analysis, GSK stock appears to be overvalued. The current stock price of MXN901.11 is trading 10% above its estimated GF Value™ of MXN818.82. GuruFocus considers GSK to be Fairly Valued.

Key valuation signals for MEX:GSKN:

  • Piotroski F-Score: 8 (33% above median its 10-year median of 6.00)
  • GF Value™: MXN818.82 vs. price of MXN901.11 (10% above fair value)
  • GF Score™: 73/100 with 1 warning sign
  • Industry Position: 60% above the Drug Manufacturers median (#16 of 981)

No single metric tells the full story. See the MEX:GSKN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GSK Business Description

Address 79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
73GF Score

Get the complete analysis for MEX:GSKN

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN901.11
Price
MXN818.82
GF Value